• Consensus Rating: Buy
  • Consensus Price Target: $13.41
  • Forecasted Upside: -1.38%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.35 (2.64%)

This chart shows the closing price for ACCD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Accolade Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACCD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACCD

Analyst Price Target is $13.41
▼ -1.38% Downside Potential
This price target is based on 16 analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $13.41, with a high forecast of $16.00 and a low forecast of $9.00. The average price target represents a -1.38% upside from the last price of $13.60.

This chart shows the closing price for ACCD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 polled investment analysts is to buy stock in Accolade. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2023GuggenheimUpgradeNeutral ➝ Buy$16.00Low
2/9/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$14.00Low
2/1/2023Raymond JamesInitiated CoverageOutperform$15.00Low
1/30/2023Truist FinancialBoost TargetBuy$12.00 ➝ $14.00Low
1/10/2023Needham & Company LLCReiterated RatingBuy$15.00Low
1/10/2023DA DavidsonLower Target$16.00 ➝ $14.00Low
1/6/2023Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00Low
10/12/2022Wells Fargo & CompanyBoost TargetEqual Weight$8.00 ➝ $10.00Low
10/7/2022Credit Suisse GroupBoost TargetNeutral$9.00 ➝ $11.00Low
10/7/2022The Goldman Sachs GroupBoost TargetBuy$14.50 ➝ $16.00Low
10/7/2022SVB LeerinkBoost TargetMarket Perform$8.00 ➝ $13.00Low
10/4/2022Needham & Company LLCBoost TargetBuy$12.00 ➝ $15.00Low
10/4/2022Piper SandlerBoost TargetOverweight$12.00 ➝ $13.00Low
10/3/2022Canaccord Genuity GroupBoost TargetBuy$12.00 ➝ $15.00Low
10/3/2022Canaccord Genuity GroupBoost Target$12.00 ➝ $15.00Low
9/21/2022The Goldman Sachs GroupBoost TargetBuy$13.00 ➝ $14.50Low
9/14/2022Morgan StanleyBoost TargetEqual Weight$9.00 ➝ $12.00Low
9/8/2022Piper SandlerReiterated RatingOverweight$12.00Low
9/7/2022Truist FinancialInitiated CoverageBuy$15.00Low
8/12/2022DA DavidsonInitiated CoverageBuy$16.00Low
7/5/2022Wells Fargo & CompanyBoost TargetEqual Weight$6.00 ➝ $8.00N/A
7/1/2022Berenberg BankReiterated RatingBuy$11.00Low
7/1/2022Canaccord Genuity GroupLower TargetBuy$17.00 ➝ $12.00Low
7/1/2022Canaccord Genuity GroupLower Target$17.00 ➝ $12.00Low
7/1/2022The Goldman Sachs GroupLower TargetBuy$15.00 ➝ $13.00Low
6/17/2022Berenberg BankReiterated RatingBuy$11.00Low
5/26/2022The Goldman Sachs GroupLower TargetBuy$26.00 ➝ $15.00Low
5/2/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$6.00High
4/29/2022Canaccord Genuity GroupLower Target$34.00 ➝ $17.00High
4/29/2022Stifel NicolausLower Target$16.00High
4/29/2022Needham & Company LLCLower Target$33.00 ➝ $12.00High
4/29/2022BTIG ResearchDowngradeBuy ➝ NeutralHigh
4/29/2022Bank of AmericaDowngradeBuy ➝ Neutral$45.00 ➝ $9.00High
4/29/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$32.00 ➝ $8.00High
4/29/2022Piper SandlerLower Target$22.00 ➝ $11.00High
4/29/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$30.00 ➝ $9.00High
4/29/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$33.00 ➝ $9.00High
4/13/2022Piper SandlerLower Target$35.00 ➝ $22.00Medium
4/11/2022Wells Fargo & CompanyInitiated CoverageUnderweight$9.00High
4/6/2022GuggenheimInitiated CoverageNeutralMedium
4/1/2022Credit Suisse GroupInitiated CoverageOutperform$33.00Medium
3/3/2022Credit Suisse GroupLower TargetOutperform$43.00 ➝ $33.00Medium
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$32.00High
1/11/2022BTIG ResearchLower Target$60.00 ➝ $35.00High
1/11/2022Stifel NicolausLower Target$40.00 ➝ $34.00High
1/11/2022Morgan StanleyLower TargetOverweight$31.00 ➝ $30.00High
1/11/2022Piper SandlerLower Target$45.00 ➝ $35.00High
1/11/2022Needham & Company LLCLower TargetBuy$56.00 ➝ $33.00High
12/17/2021Morgan StanleyLower TargetOverweight$56.00 ➝ $31.00High
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$33.00High
10/11/2021Morgan StanleyLower TargetOverweight$68.00 ➝ $56.00High
10/8/2021Berenberg BankReiterated RatingBuy$61.00High
10/8/2021Credit Suisse GroupLower TargetOutperform$63.00 ➝ $62.00Medium
10/8/2021Piper SandlerLower TargetPositive ➝ Overweight$60.00 ➝ $45.00High
10/8/2021Needham & Company LLCLower TargetBuy$68.00 ➝ $56.00High
10/8/2021SVB LeerinkLower TargetOutperform$58.00 ➝ $52.00High
9/30/2021Berenberg BankInitiated CoverageBuy$61.00Medium
9/17/2021Robert W. BairdUpgradeNeutral ➝ Outperform$58.00 ➝ $54.00Low
7/13/2021Robert W. BairdBoost TargetNeutral$54.00 ➝ $58.00Low
7/11/2021SVB LeerinkInitiated CoverageBuy$58.00Low
7/9/2021Stifel NicolausBoost TargetBuy$54.00 ➝ $64.00Low
7/9/2021Needham & Company LLCBoost TargetPositive ➝ Buy$59.00 ➝ $68.00Medium
7/7/2021Credit Suisse GroupBoost TargetOutperform$59.00 ➝ $70.00High
7/2/2021Morgan StanleyBoost TargetOverweight$60.00 ➝ $68.00Low
5/27/2021Robert W. BairdInitiated CoverageNeutral$54.00Medium
5/6/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
4/27/2021SVB LeerinkReiterated RatingHoldMedium
4/15/2021Needham & Company LLCInitiated CoverageBuy$59.00Medium
4/6/2021Morgan StanleyBoost TargetOverweight$57.00 ➝ $60.00High
3/11/2021The Goldman Sachs GroupInitiated CoverageBuyHigh
2/16/2021Piper SandlerBoost TargetOverweight$57.00 ➝ $60.00Low
1/15/2021BTIG ResearchBoost TargetPositive ➝ Buy$55.00 ➝ $60.00High
1/15/2021Robert W. BairdBoost TargetOutperform$50.00 ➝ $55.00High
1/15/2021SVB LeerinkBoost TargetMarket Perform$53.00 ➝ $56.00High
1/15/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00 ➝ $60.00High
1/8/2021Credit Suisse GroupBoost TargetNeutral ➝ Neutral$42.00 ➝ $45.00High
1/8/2021Robert W. BairdBoost TargetPositive ➝ Outperform$45.00 ➝ $50.00High
1/8/2021SVB LeerinkBoost TargetMarket Perform$44.00 ➝ $53.00High
1/8/2021Piper SandlerBoost TargetOverweight$55.00 ➝ $57.00High
1/6/2021BTIG ResearchInitiated CoverageBuy$55.00N/A
11/16/2020Stifel NicolausInitiated CoverageBuy$48.00High
10/16/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $48.00Medium
10/15/2020Bank of AmericaBoost TargetBuy$45.00 ➝ $51.00High
10/15/2020DA DavidsonBoost TargetPositive ➝ Buy$45.00 ➝ $50.00High
10/15/2020SVB LeerinkBoost TargetMarket Perform$40.00 ➝ $44.00Low
10/15/2020Robert W. BairdBoost TargetOutperform$40.00 ➝ $45.00Low
10/15/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $55.00Low
10/8/2020Bank of AmericaBoost TargetBuy$42.50 ➝ $45.00Medium
9/22/2020DA DavidsonInitiated CoverageBuy$45.00High
8/14/2020Credit Suisse GroupBoost TargetNeutral$38.00 ➝ $40.00High
8/14/2020SVB LeerinkBoost TargetMarket Perform$34.00 ➝ $40.00High
7/27/2020Robert W. BairdInitiated CoverageOutperform$40.00High
7/27/2020SVB LeerinkInitiated CoverageOutperform$34.00High
7/27/2020Bank of AmericaInitiated CoverageBuy$37.00High
7/27/2020Piper SandlerInitiated CoverageOverweight$45.00High
7/27/2020The Goldman Sachs GroupInitiated CoverageBuy$39.00High
7/27/2020Credit Suisse GroupInitiated CoverageNeutral$38.00High
7/27/2020Morgan StanleyInitiated CoverageOverweight$37.00High
(Data available from 3/24/2018 forward)

News Sentiment Rating

1.30 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.
Accolade logo
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $13.60
Low: $13.09
High: $13.86

50 Day Range

MA: $11.52
Low: $8.90
High: $13.30

52 Week Range

Now: $13.60
Low: $4.61
High: $19.39


250,939 shs

Average Volume

708,385 shs

Market Capitalization

$989.94 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Accolade?

The following Wall Street sell-side analysts have issued research reports on Accolade in the last year: Bank of America Co., Berenberg Bank, BTIG Research, Canaccord Genuity Group Inc., Credit Suisse Group AG, DA Davidson, Guggenheim, Jefferies Financial Group Inc., Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for ACCD.

What is the current price target for Accolade?

17 Wall Street analysts have set twelve-month price targets for Accolade in the last year. Their average twelve-month price target is $13.41, suggesting a possible upside of 1.2%. The Goldman Sachs Group, Inc. has the highest price target set, predicting ACCD will reach $16.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $9.00 for Accolade in the next year.
View the latest price targets for ACCD.

What is the current consensus analyst rating for Accolade?

Accolade currently has 7 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACCD will outperform the market and that investors should add to their positions of Accolade.
View the latest ratings for ACCD.

What other companies compete with Accolade?

How do I contact Accolade's investor relations team?

Accolade's physical mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 206-926-8100 and its investor relations email address is [email protected] The official website for Accolade is accolade.com. Learn More about contacing Accolade investor relations.